RRM2B deficiency causes dATP and dGTP depletion through enhanced degradation and slower synthesis
Proceedings of the National Academy of Sciences · 22.04.2025 · 122 (16)
DOI: 10.1073/pnas.2503531122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 17.04.2025. Verfasst von Ololade Folajimi Awoyomi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry and Biophysics, Umeå University, Umeå SE 90187, Sweden. Hauptthemen laut MEDLINE: Ribonucleotide Reductases, Deoxyadenine Nucleotides, Deoxyguanine Nucleotides, Ribonucleoside Diphosphate Reductase. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Vetenskapsrådet (VR), Cancerfonden (Swedish Cancer Society), Knut och Alice Wallenbergs Stiftelse (Knut and Alice Wallenberg Foundation).
Abstract (Originalsprache)
Mitochondrial DNA (mtDNA) replication requires a steady supply of deoxyribonucleotides (dNTPs), synthesized de novo by ribonucleotide reductase (RNR). In nondividing cells, RNR consists of RRM1 and RRM2B subunits. Mutations in RRM2B cause mtDNA depletion syndrome, linked to muscle weakness, neurological decline, and early mortality. The impact of RRM2B deficiency on dNTP pools in nondividing tissues remains unclear. Using a mouse knockout model, we demonstrate that RRM2B deficiency selectively depletes dATP and dGTP, while dCTP and dTTP levels remain stable or increase. This depletion pattern resembles the effects of hydroxyurea, an inhibitor that reduces overall RNR activity. Mechanistically, we propose that the depletion of dATP and dGTP arises from their preferred degradation by the dNTPase SAMHD1 and the lower production rate of dATP by RNR. Identifying dATP and dGTP depletion as a hallmark of RRM2B deficiency provides insights for developing nucleoside bypass therapies to alleviate the effects of RRM2B mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biochemistry and Biophysics, Umeå University, Umeå SE 90187, Sweden.
ORCID-Profile: Ololade Folajimi Awoyomi, Sushma Sharma, Olena Diachenko, Phong Tran, Paulina H Wanrooij, Andrei Chabes
Förderung
- Vetenskapsrådet (VR)
- Cancerfonden (Swedish Cancer Society)
- Knut och Alice Wallenbergs Stiftelse (Knut and Alice Wallenberg Foundation)
Zitieren
APA
Awoyomi, O. F., Gorospe, C. M., Das, B., Mishra, P., Sharma, S., Diachenko, O., Nilsson, A. K., Tran, P., Wanrooij, P. H., & Chabes, A. (2025). RRM2B deficiency causes dATP and dGTP depletion through enhanced degradation and slower synthesis. Proceedings of the National Academy of Sciences, 122(16). https://doi.org/10.1073/pnas.2503531122
Vancouver
Awoyomi OF, Gorospe CM, Das B, Mishra P, Sharma S, Diachenko O, et al. RRM2B deficiency causes dATP and dGTP depletion through enhanced degradation and slower synthesis. Proceedings of the National Academy of Sciences. 2025;122(16). doi:10.1073/pnas.2503531122
BibTeX
@article{Awoyomi2025,
author = {Awoyomi, Ololade Folajimi and Gorospe, Choco Michael and Das, Biswajit and Mishra, Pradeep and Sharma, Sushma and Diachenko, Olena and Nilsson, Anna Karin and Tran, Phong and Wanrooij, Paulina H and Chabes, Andrei},
title = {RRM2B deficiency causes dATP and dGTP depletion through enhanced degradation and slower synthesis},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
volume = {122},
number = {16},
doi = {10.1073/pnas.2503531122}
}
EUVIMED